{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-223262","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.795411+00:00","generated_at":"2026-05-17T05:22:23.460730+00:00","sec_items":["1.01","8.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"KalVista closes $143.75M convertible notes offering; net proceeds ~$139M for EKTERLY","bullets":["Issued $143.75M in 3.250% Convertible Senior Notes due 2031, including full exercise of $18.75M greenshoe.","Net proceeds ~$139M after discounts and expenses; used for working capital and EKTERLY commercialization.","Initial conversion rate 59.4919 shares/$1,000 (conversion price ~$16.81), 30% premium over $12.93 close.","Notes are senior, unsecured, callable after Oct 5, 2028 if stock price meets 130% conversion price threshold."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-223262","json":"https://secwatch.observer/filing/0001193125-25-223262.json","markdown":"https://secwatch.observer/filing/0001193125-25-223262.md","text":"https://secwatch.observer/filing/0001193125-25-223262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525223262/0001193125-25-223262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525223262/d83242d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:22:23.460730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"adc3520005e021db988511bed2d3608a24251632","claim":"KalVista Pharmaceuticals, Inc. incurred convertible notes of $143.75 million in aggregate principal amount with Initial Purchasers at 3.250% maturing due 2031.","evidence_excerpt":"On September 29, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) completed its previously announced sale of $143.75 million in aggregate principal amount of its 3.250% Convertible Senior Notes due 2031","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525223262/0001193125-25-223262-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$143.75 million in aggregate principal amount"},{"label":"Counterparty","value":"Initial Purchasers"},{"label":"Rate","value":"3.250%"},{"label":"Maturity","value":"due 2031"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}